AL-794

DRUG3 trials

Sponsors

Alios Biopharma Inc.

Conditions

HealthyInfluenzaInfluenza in Humans

Phase 1

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

CompletedNCT02588521

Alios Biopharma Inc.Influenza

Start: 2015-08-31End: 2017-08-14Updated: 2017-10-11

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

CompletedNCT02888327

Alios Biopharma Inc.Influenza in Humans

Start: 2016-07-31End: 2017-05-30Updated: 2025-02-03

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers

TerminatedNCT03411421

Alios Biopharma Inc.Healthy

Start: 2018-03-03End: 2018-04-27Updated: 2025-02-03

Related Papers

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

The Journal of Infectious Diseases2018-07-0723 citations